Therefore, in order to clarify the impact and potential mechanisms of EGFRvIII mutation on the immune microenvironment in GBM, through a series of molecular biology experiments, it was demonstrated that EGFRvIII-mutated GBM is directly involved in the regulation of MDK expression through the ERK/c-Fos signaling pathway. The gene discussed is FOS; the disease is glioblastoma.